Description: Electronic Health Records are here to stay. Take a deep dive into the world of electronic health records and how the industry is poised to utilize this new form of digital medical data to transform the way policies are underwritten and ultimately, transforming the client experience. Listen to industry experts speak about what they are doing to use this data most effectively and how this ultimately develops into ground-breaking solutions for the industry.

Description: Generative artificial intelligence (AI) tools like ChatGPT will redefine the nature of work across industries in coming years, What does this mean for the actuarial profession? Delivering generative AI tools to actuaries capable of leveraging them effectively will dramatically modernize how actuaries work and contribute to organizational growth. In this educational session, explore how generative AI can accelerate actuarial model development. Gain an introduction to generative AI and its implications for actuarial modeling. Learn how it specifically helps actuaries improve accuracy, reduce errors and save time in model development. Then explore use cases, including how generative AI can improve data cleaning, model building, as well as simulate scenarios and test model robustness. Close with a discussion on how to integrate generative AI into actuarial modeling workflows effectively, including common challenges actuaries may face during implementation and tips to overcome them. You will come away with a deeper understanding of how generative AI can accelerate actuarial model development.

Description: Regression to the mean (RTTM) is inflating your health care intervention evaluations if you are not carefully managing it's omnipresent and significant impact RTTM is the statistical phenomenon which arises when comparing sequential data points when an initial observation is extreme or an outlier, and states that with no other intervention, future observations will be closer to the average. Members who had high costs last year will, on average, have lower costs this year, even in the absence of any intervention or clinical program, simply by 'regressing' to the mean. This means that if your clinical programs are simply targeting members who had adverse medical experience last year, you’re targeting the wrong people. And if your savings methodologies are simply last year’s costs minus this year’s costs, the savings are inflated. By attending this session, you will be able to identify situations where RTTM will be a significant factor, how to eliminate it's impact when performing retrospective evaluations, how to identify prospects for clinical intervention with RTTM in mind, and more.

Description: Emerging Applications of ESG Methods offers ground-up insights on cutting edge applications of economic scenario generation. The course will focus on the incorporation of climate change risk in scenario modeling and investment applications of ESGs. The following topics will be covered: Approaches to climate risk modeling. Climate risk is very different than classical financial economic risk. Radical uncertainty is amenable to scenario analysis and lack of data. Building special deterministic scenarios that go beyond NGFS requirements as well as bespoke scenarios. Holistic Approach to Climate Risk Modeling. Overview of different Climate Risk Modeling Applications. Use of ESG scenarios for Strategic Asset Allocation (SAA). Liquidity risk management.

Description: Enjoy an in-depth walkthrough of the facets of the lab testing world in this webcast. The agenda will include a discussion on genetic testing, which focuses on its general background, current trends and tests in the pipeline, as well as a focus on the approaches to achieve savings in lab testing. Finally, expect to check out sample actuarial analyses that will be used to identify areas of focus in lab management. Join us and take a deeper look into lab work in the actuarial health industry.

Description: Analyze the market volatility behavior in context with historical extreme events during this webcast. There will be a focus on understanding volatility clustering and relationships, both contemporary and temporal, in addition to key economic and capital market variables. You'll also learn from a comprehensive attribution analysis, which uses economic data, asset data, retail investor data and event data as explanatory variables. Dive into investment-related Reddit comments used to capture features of retail investors and tree-based models, including Random Forests and Gradient Boosting Machines to justify changes in volatility modeling. Expect this webcast to end with an example of liability-driven investment optimization that illustrates the potential impact of increased volatility assumption, how to adopt stochastic volatility models, how to reflect volatility clustering and return jumps.

Description: "Hear AM Best rating analysts discuss the rating process and the best capital adequacy ratio (BCAR), a quantitative foundation for AM Best’s assessment of carriers’ financial strength. The benchmarking of BCAR scores for various company types (national MCOs, BCBS plans, smaller regional plans) will be discussed. Look at how changes in investment and underwriting environment impacted the results over the past several years. Further, AM Best’s view of the quality of capital and various factors impacting the overall assessment of the balance sheet strength will be discussed. By attending this session, you will: Gain an understanding of AM Best’s building block approach to ratings and how the BCAR results fit into the process. Learn the differences between RBC and BCAR models. Learn how various factors—e.g. liquidity, financial flexibility, financial leverage, the org structure—impact the final AM Best assessment of health companies' capital."

Description: Health care has changed rapidly over the past couple of years. The pandemic has shifted consumer behavior in how and where they receive health care as well as consumer attitudes toward health care. Payers continue to design innovative solutions in responses to their patient’s needs and expectations. These changes in consumer behaviors and the responses by payers are expected to impact both health care cost and utilization. Discuss changes in health care that have emerged due to the pandemic and how they are expected to influence actuarial assumptions. Explore epidemiological models commonly used in the industry, the considerations when using these models, as well as the challenges with regards to gathering and interpreting relevant experience data. By attending this session, you will be able to: Identify shifts in consumer behavior that have emerged from the pandemic and describe how payers are responding to new patient expectations. Discuss how these post-pandemic changes by consumers and payers influence medical spending. Determine which actuarial assumptions are impacted and how and if the impact is expected to be temporary or permanent. Discuss considerations taken by actuaries and challenges faced when modelling actuarial assumptions post pandemic.

Description: ALM and hedging can reap significant benefits from innovation in computation and operations research. Explore applications of static and dynamic optimization in two different ALM and hedging use cases. Insurers are increasingly moving offshore by establishing Bermuda captive reinsurers. In calculating the Bermuda Best Estimate Liability ('BEL'), reinsurers will need to segment assets to support liabilities in each treaty. A Linear Programming ('LP') problem can be formulated to tactically select assets in a way that minimizes the BEL and consequently the total asset requirement. Learn more about what US Variable Annuity Insurers face with the regulatory requirement to reflect 'future hedging strategy' in their statutory funding calculation. The traditional numerical method of finding the optimal hedging target and then allocating assets may encounter the curse of dimensionality with expanding product and economic environment complexity. A Reinforcement Learning algorithm may well fit this problem and provide insurers a solution for dynamic hedging.

Description: Actuaries historically modeled new launches in pharmaceuticals by anticipating the expected change to the market basket. This became more complicated with the recent launches of gene and cell therapies as they address rare diseases. Rare conditions have low total member volume to study and some do not currently have a diagnosis code to identify them within claims data. Addressing this modeling challenge has been growing more important in the recent years with the number of therapies launching. What has the health care industry, and more specifically health care, done to enhance modeling and how should this be altered for the future? Additionally, historic modeling has sometimes incorporated a level of direct medical treatment cost offsets where studies have shown lower treatment costs are achievable. Can gene and cell financial modeling include cost offsets as well? And if so, what are suggested precautions or limitations to this effort?